Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trialFrancesco Perrone, A. De Matteis, Emanuela Rossi et al.|Annals of Oncology|2014Cited by 68
The HOBOE-2 multicenter randomized phase III trial in premenopausal patients with hormone-receptor positive early breast cancer comparing triptorelin plus either tamoxifen or letrozole or letrozole + zoledronic acidFranco Perrone, Ciro Gallo, Michelino De Laurentiis et al.|Annals of Oncology|2018Cited by 12
Weekly Docetaxel (Wd) Vs Cmf As Adjuvant Chemotherapy for Elderly Early Breast Cancer (Ebc) Patients (Pts): Final Results from the Randomised Phase 3 Elda TrialFrancesco Perrone, A. De Matteis, Francesco Nuzzo et al.|Annals of Oncology|2014Cited by 1
P920. Breast cancer with more than 3 positive nodes: adjuvant epirubicin followed by CMF +/- hormonotherapy. Preliminary resultsA. De Matteis, Alfonso Maiorino, Rimisha Thomas et al.|The Breast|1997Cited by 0